Literature DB >> 34271857

The prognostic value of circulating tumour cells (CTCs) and CTC white blood cell clusters in patients with renal cell carcinoma.

Yibing Guan1,2, Fangshi Xu1,2, Juanhua Tian1,2, Ke Gao1,2, Ziyan Wan1,2, Yiyuan Wang3, Mei Gao1, Zhenlong Wang1, Tie Chong4.   

Abstract

PURPOSE: Circulating tumour cell (CTC) and CTC-white blood cell (CTC-WBC) clusters are related to the prognosis of tumour patients. However, the relationship between CTC-WBC clusters and prognosis in renal cell carcinoma (RCC) patients is not clear. We evaluated the prognostic value of CTC-WBC clusters using metastasis-free survival (MFS) and overall survival (OS) in patients with RCC.
MATERIALS AND METHODS: The baseline, survival, and CTC data of patients with RCC were statistically analysed by R.
RESULTS: The Cox risk proportional regression model suggests that the total CTCs, pathology type, and CTC-WBC clusters can be used as prognostic indicators for the MFS of RCC patients. Total CTCs and solid tumour diameter can be used as prognostic indicators for the OS of RCC patients. Using Kaplan-Meier survival analysis, we found that patients with total CTCs, pathology, and CTC-WBC clusters greater than the cut-off value had a worse MFS, and patients with total CTCs greater than the cut-off value had a worse OS.
CONCLUSION: The analysis of the clinical sample data in patients with RCC shows that CTC-WBC clusters play an important role in monitoring the prognosis of RCC. Among them, total CTCs, pathology, and CTC-WBC clusters were combined as prognostic factors for the MFS of RCC patients. Total CTCs and solid tumour diameter can be combined as prognostic factors for the OS of RCC patients. These prognostic factors provide more convenient and accurate condition monitoring for renal cancer patients and can be used to actively improve the prognosis of patients.
© 2021. The Author(s).

Entities:  

Keywords:  CTC-WBC cluster; Circulating tumour cells; Metastasis-free survival; Prognosis; Renal cell carcinoma

Year:  2021        PMID: 34271857     DOI: 10.1186/s12885-021-08463-7

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  21 in total

1.  Pathology of circulating tumor cells and the available capture tools (Review).

Authors:  Yibing Guan; Fangshi Xu; Juanhua Tian; Hongwei Chen; Chuance Yang; Shanlong Huang; Ke Gao; Ziyan Wan; Mingrui Li; Minxin He; Tie Chong
Journal:  Oncol Rep       Date:  2020-03-06       Impact factor: 3.906

Review 2.  Systemic Therapy for Metastatic Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Robert J Motzer
Journal:  N Engl J Med       Date:  2017-01-26       Impact factor: 91.245

Review 3.  Renal cell carcinoma.

Authors:  James J Hsieh; Mark P Purdue; Sabina Signoretti; Charles Swanton; Laurence Albiges; Manuela Schmidinger; Daniel Y Heng; James Larkin; Vincenzo Ficarra
Journal:  Nat Rev Dis Primers       Date:  2017-03-09       Impact factor: 52.329

Review 4.  Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.

Authors:  Malte Mohme; Sabine Riethdorf; Klaus Pantel
Journal:  Nat Rev Clin Oncol       Date:  2016-09-20       Impact factor: 66.675

5.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.

Authors:  Massimo Cristofanilli; Daniel F Hayes; G Thomas Budd; Mathew J Ellis; Alison Stopeck; James M Reuben; Gerald V Doyle; Jeri Matera; W Jeffrey Allard; M Craig Miller; Herbert A Fritsche; Gabriel N Hortobagyi; Leon W M M Terstappen
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

6.  Neutrophils escort circulating tumour cells to enable cell cycle progression.

Authors:  Barbara Maria Szczerba; Francesc Castro-Giner; Marcus Vetter; Ilona Krol; Sofia Gkountela; Julia Landin; Manuel C Scheidmann; Cinzia Donato; Ramona Scherrer; Jochen Singer; Christian Beisel; Christian Kurzeder; Viola Heinzelmann-Schwarz; Christoph Rochlitz; Walter Paul Weber; Niko Beerenwinkel; Nicola Aceto
Journal:  Nature       Date:  2019-02-06       Impact factor: 49.962

7.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

Review 8.  Recent advances in the treatment of metastatic renal cell carcinoma.

Authors:  Hideyuki Abe; Takao Kamai
Journal:  Int J Urol       Date:  2013-05-21       Impact factor: 3.369

9.  Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or predictive of recurrence in hepatocellular carcinoma.

Authors:  Yunyang Chen; Shaoming Li; Wei Li; Rongbing Yang; Xianguang Zhang; Yong Ye; Jiexiong Yu; Lin Ye; Wangrong Tang
Journal:  Sci Rep       Date:  2019-05-08       Impact factor: 4.379

View more
  2 in total

1.  Advances in Microfluidics for the Implementation of Liquid Biopsy in Clinical Routine.

Authors:  Alexandra Teixeira; Adriana Carneiro; Paulina Piairo; Miguel Xavier; Alar Ainla; Cláudia Lopes; Maria Sousa-Silva; Armando Dias; Ana S Martins; Carolina Rodrigues; Ricardo Pereira; Liliana R Pires; Sara Abalde-Cela; Lorena Diéguez
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

2.  Analysis of the prognostic role and biological characteristics of circulating tumor cell-associated white blood cell clusters in non-small cell lung cancer.

Authors:  Zheng Li; Liwen Fan; Yun Wu; Yuxu Niu; Xuelin Zhang; Bin Wang; Yuanshan Yao; Chunji Chen; Ning Qi; Daisy Dandan Wang; Peter Ping Lin; Dongfang Tang; Wen Gao
Journal:  J Thorac Dis       Date:  2022-05       Impact factor: 3.005

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.